By inhibiting IL-4R alpha in aspirin-exacerbated respiratory disease, dupilumab improved respiratory symptoms and smell among other positive outcomes, according to a study published in The Journal of Allergy and Clinical Immunology.
These therapeutic effects likely are due to decreased IL-4R alpha signaling on respiratory tissue granulocytes, epithelial cells and B cells, Kathleen M. Buchheit, MD, assistant professor of medicine in the division of allergy and clinical immunology at Harvard Medical School and assistant program director of the allergy/immunology fellowship at Brigham and Women’s